Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

general manager of Novo Nordisk UK. "Our smart connected insulin pens aim to empower people to better understand their diabetes management, have more informed conversations with their doctor and ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

The insulin pen was a gamechanger: discreet and easy to transport. Which is why she's so "angry" at "how much harder" Novo Nordisk has made her life with its decision to stop producing human ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

A Novo Nordisk official said the company makes more than a dozen insulin products and more than 800 million insulin pens a year. "Not only are we not winding down our work for people living with ...

Novo Nordisk remains a sell due to increased competition ... with a 54.8% market share in GLP-1 and a 43.9% market share in insulin (33.8% total diabetes market share). As this share has grown ...